Qingxia Chen1, Marie R Griffin2, Hui Nian3, Yuwei Zhu3, John V Williams4, Kathryn M Edwards5, H Keipp Talbot6. 1. Department of Biostatistics Department of Biomedical Informatics, Vanderbilt University Medical Center. 2. Department of Preventive Medicine Department of Medicine Department of Mid-South Geriatric Research Education and Clinical Center Department of Clinical Research Center of Excellence, VA Tennessee Valley Health Care System, Nashville, Tennessee. 3. Department of Biostatistics. 4. Department of Pediatrics Department of Microbiology and Immunology. 5. Department of Pediatrics. 6. Department of Medicine.
Abstract
BACKGROUND: There are few estimates of effectiveness influenza vaccine in preventing serious outcomes due to influenza in older adults. METHODS: Adults aged ≥50 years who sought medical care for acute respiratory illness were enrolled. A nose/throat swab was tested for influenza virus by reverse transcription-polymerase chain reaction. Clinical and demographic data were collected, including verification of receipt of trivalent inactivated influenza vaccination (IIV-3). Adjusted odds ratios were estimated by multivariable logistic regression models with an L1 penalty on all covariates except vaccination status. RESULTS: A total of 1047 subjects were enrolled from November through April during 5 influenza seasons during 2006-2012, excluding the 2009-2010 season. Of those enrolled, 927 (88%) had complete influenza virus testing, vaccination status, and demographic data obtained. Of 86 (9.3%) influenza virus-positive patients, 47 (55%) were vaccinated. Of 841 influenza virus-negative patients, 646 (76.8%) were vaccinated. Over 5 influenza seasons, IIV-3 was 58.4% effective (95% confidence interval [CI], 37.0%-75.6%) for the prevention of medically attended laboratory-confirmed influenza illness in adults aged ≥50 years and 58.4% effective (95% CI, 7.9%-81.1%) in adults aged ≥65 years. CONCLUSIONS: Influenza vaccine was moderately effective in preventing influenza-associated medical care visits in older adults.
BACKGROUND: There are few estimates of effectiveness influenza vaccine in preventing serious outcomes due to influenza in older adults. METHODS: Adults aged ≥50 years who sought medical care for acute respiratory illness were enrolled. A nose/throat swab was tested for influenza virus by reverse transcription-polymerase chain reaction. Clinical and demographic data were collected, including verification of receipt of trivalent inactivated influenza vaccination (IIV-3). Adjusted odds ratios were estimated by multivariable logistic regression models with an L1 penalty on all covariates except vaccination status. RESULTS: A total of 1047 subjects were enrolled from November through April during 5 influenza seasons during 2006-2012, excluding the 2009-2010 season. Of those enrolled, 927 (88%) had complete influenza virus testing, vaccination status, and demographic data obtained. Of 86 (9.3%) influenza virus-positive patients, 47 (55%) were vaccinated. Of 841 influenza virus-negative patients, 646 (76.8%) were vaccinated. Over 5 influenza seasons, IIV-3 was 58.4% effective (95% confidence interval [CI], 37.0%-75.6%) for the prevention of medically attended laboratory-confirmed influenza illness in adults aged ≥50 years and 58.4% effective (95% CI, 7.9%-81.1%) in adults aged ≥65 years. CONCLUSIONS:Influenza vaccine was moderately effective in preventing influenza-associated medical care visits in older adults.
Authors: H Keipp Talbot; Yuwei Zhu; Qingxia Chen; John V Williams; Mark G Thompson; Marie R Griffin Journal: Clin Infect Dis Date: 2013-02-28 Impact factor: 9.079
Authors: J Castilla; I Martínez-Baz; A Navascués; M Fernandez-Alonso; G Reina; M Guevara; J Chamorro; M T Ortega; E Albéniz; F Pozo; C Ezpeleta Journal: Euro Surveill Date: 2014-02-13
Authors: Jesús Castilla; Pere Godoy; Angela Domínguez; Iván Martínez-Baz; Jenaro Astray; Vicente Martín; Miguel Delgado-Rodríguez; Maretva Baricot; Nuria Soldevila; José María Mayoral; José María Quintana; Juan Carlos Galán; Ady Castro; Fernando González-Candelas; Olatz Garín; Marc Saez; Sonia Tamames; Tomás Pumarola Journal: Clin Infect Dis Date: 2013-03-26 Impact factor: 9.079
Authors: Brendan Flannery; Swathi N Thaker; Jessie Clippard; Arnold S Monto; Suzanne E Ohmit; Richard K Zimmerman; Mary Patricia Nowalk; Manjusha Gaglani; Michael L Jackson; Lisa A Jackson; Edward A Belongia; Huong Q McLean; LaShondra Berman; Angie Foust; Wendy Sessions; Sarah Spencer; Alicia M Fry Journal: MMWR Morb Mortal Wkly Rep Date: 2014-02-21 Impact factor: 17.586
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Melissa K Andrew; Vivek Shinde; Lingyun Ye; Todd Hatchette; François Haguinet; Gael Dos Santos; Janet E McElhaney; Ardith Ambrose; Guy Boivin; William Bowie; Ayman Chit; May ElSherif; Karen Green; Scott Halperin; Barbara Ibarguchi; Jennie Johnstone; Kevin Katz; Joanne Langley; Jason Leblanc; Mark Loeb; Donna MacKinnon-Cameron; Anne McCarthy; Allison McGeer; Jeff Powis; David Richardson; Makeda Semret; Grant Stiver; Sylvie Trottier; Louis Valiquette; Duncan Webster; Shelly A McNeil Journal: J Infect Dis Date: 2017-08-15 Impact factor: 5.226
Authors: George N Okoli; Florentin Racovitan; Christiaan H Righolt; Salaheddin M Mahmud Journal: Open Forum Infect Dis Date: 2020-05-21 Impact factor: 3.835
Authors: Robert G Deiss; John C Arnold; Wei-Ju Chen; Sara Echols; Mary P Fairchok; Christina Schofield; Patrick J Danaher; Erin McDonough; Michelande Ridoré; Deepika Mor; Timothy H Burgess; Eugene V Millar Journal: Vaccine Date: 2015-11-10 Impact factor: 3.641
Authors: Mary Louise Lindegren; Marie R Griffin; John V Williams; Kathryn M Edwards; Yuwei Zhu; Ed Mitchel; Alicia M Fry; William Schaffner; H Keipp Talbot Journal: PLoS One Date: 2015-03-25 Impact factor: 3.240